ArticleThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2025
Uncommon neuromyopathy toxicity induced by amiodarone therapy: case report.
Article in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Muscle toxicity reports in FAERS: a disproportionality analysis with focus on rhabdomyolysis and cross-database assessment.Frontiers in pharmacology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmiodarone is an antiarrhythmic drug known for its potential side effects, one of which is neuromyopathy, though it remains relatively rare. This condition can present with muscle weakness, pain, and tremors, potentially leading to functional impairment. The exact mechanisms underlying amiodarone-induced neuromyopathy are not fully understood but may involve both direct muscle toxicity and effects on nerve conduction. CASE PRESENTATION: We present the case of a 68-year-old man with symptomatic arrhythmogenic right ventricular dysplasia, receiving long-term amiodarone, experiencing bilateral leg pain and weakness associated with amiodarone use. On clinical examination, motor strength in the lower limbs was rated at 2/5, with decreased tactile sensation. The biological assessment showed normal level of creatine kinase and C-reactive protein. The spinal MRI was normal. Electromyography "EMG" revealed a non-length dependent sensorimotor demyelinating polyneuropathy. After discontinuing amiodarone, both mobility and function showed significant improvement.
conclusionThese observations highlight the importance of performing neurologic examinations in patients treated with amiodarone to identify even rare complications, such as neuromyopathy. Importantly, neuromyopathy is often reversible following discontinuation of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.